Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5
Benzinga Newsdesk 8 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.